论文部分内容阅读
目的:研究Egfl7与非小细胞肺癌(NSCLC)上皮间质转化标志物E-cadherin,Vimentin的相关性,探讨Egfl7是否参与NSCLC的上皮间质转化(EMT)。方法:分别采用免疫组化法和RT-PCR法检测40例NSCLC组织和20例肺癌旁正常肺组织中Egfl7,E-cadherin和Vimentin蛋白和mRNA的表达情况。结果:1).NSCLC组织中的Egfl7蛋白和mRNA的表达水平明显高于癌旁正常肺组织;其差异有统计学意义(P<0.05)。Egfl7的表达水平与肺癌的临床分期、及淋巴结转移密切相关(p0.05)。结论:NSCLC组织中Egfl7高表达,Egfl7可能与NSCLC的侵袭性相关;Egfl7与E-cadherin呈负相关,与Vimentin表达成正相关,Egfl7可能参与了NSCLC患者的上皮间质转化(EMT)过程,阻断Egfl7信号可能会抑制NSCLC患者的ENT。
Objective: To investigate the correlation between Egfl7 and E-cadherin and Vimentin in non-small cell lung cancer (NSCLC) and to investigate whether Egfl7 is involved in epithelial-mesenchymal transition (EMT) in NSCLC. Methods: The expressions of Egfl7, E-cadherin and Vimentin in 40 NSCLC tissues and 20 normal lung tissues adjacent to lung cancer tissues were detected by immunohistochemistry and RT-PCR respectively. Results: 1) The expression of Egfl7 protein and mRNA in NSCLC tissues was significantly higher than that in adjacent normal lung tissues (P <0.05). The expression of Egfl7 was closely related to the clinical stage of lung cancer and lymph node metastasis (p <0.05); 2) The expression of E-cadherin protein and mRNA in NSCLC tissues was significantly lower than that in normal lung tissues The expression of Vimentin protein and gene in NSCLC tissues was significantly higher than that in adjacent normal lung tissues, and the expression of Vimentin in 40 cases of cancer tissues was significantly lower than that in non-metastasis cases The expression of Egfl7 was negatively correlated with E-cadherin (r = -0.34, P <0.05), but positively correlated with Vimentin expression (r = 0.297, P <0.05) ), There was no significant correlation between the expression of E-cadherin and Vimentin (r = 0.0002, P> 0.05). Conclusion: Egfl7 is highly expressed in NSCLC tissues, and Egfl7 may be involved in NSCLC invasiveness. Egfl7 is negatively correlated with E-cadherin and positively correlated with Vimentin expression. Egfl7 may be involved in the process of epithelial-mesenchymal transition (EMT) in NSCLC patients. Disruption of Egfl7 signaling may inhibit ENT in NSCLC patients.